Randomized, Multi-centre, Phase II Trial to Compare the Event-Free Survival of Clofarabine / Ara-C (ClAraC) or of FLAMSA Treatment in Patients With High Risk AML or Advanced MDS Scheduled for Allogeneic Stem Cell Transplantation
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Clofarabine (Primary) ; Amsacrine; Cytarabine; Fludarabine
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms ClAraC-SCT
Most Recent Events
- 28 Jun 2017 Status changed from recruiting to completed.
- 29 Aug 2011 New trial record